Volume 16 - Issue 3 - March 2008

In 1997 the U.S. Food and Drug Administration granted an indication for the use of the Thin-layer Rapid Use Epicutaneous (T.R.U.E.) test panels 1.1 and 2.1 as a valuable, first-line screening tool in the diagnosis of allergic contact dermatitis (ACD). Many dermatologists utilize this standard tool in their practices and refer to contact dermatitis referral centers when the T.R.U.E test fails to identify a relevant allergen. Specifically, the T.R.U.E. test screens for 46 distinct allergens and the Balsam of Peru mixture. The test is thought to adequately identify an alle